A BILL 
To amend the Public Health Service Act with respect to 
the treatment under section 351(k)(7) of such Act (relat-
ing to exclusivity for reference products) of certain prod-
ucts deemed to have a biologics license pursuant to sec-
tion 7002 of the Biologics Price Competition and Innova-
tion Act of 2009. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Protecting Access to 
4
Biosimilars Act of 2019’’. 
5
23:20 Apr 12, 2019
H2011
2 
•HR 2011 IH
SEC. 2. TREATMENT OF BIOLOGICAL PRODUCTS DEEMED 
1
LICENSED. 
2
Section 351(k)(7) of the Public Health Service Act 
3
(42 U.S.C. 262(k)(7)) is amended by adding at the end 
4
the following: 
5
‘‘(D) DEEMED LICENSES.— 
6
‘‘(i) NO
ADDITIONAL
EXCLUSIVITY 
7
THROUGH DEEMING.—An approved appli-
8
cation that is deemed to be a license for a 
9
biological product under this section pursu-
10
ant to section 7002(e)(4) of the Biologics 
11
Price Competition and Innovation Act of 
12
2009 shall not be treated as having been 
13
first licensed under subsection (a) for pur-
14
poses of subparagraphs (A) and (B). 
15
‘‘(ii) 
APPLICABILITY
OF 
16
ANTIEVERGREENING
PROVISIONS.—Sub-
17
paragraph (C) shall apply to any reference 
18
product, without regard to whether— 
19
‘‘(I) such product was first li-
20
censed under subsection (a); or 
21
‘‘(II) the approved application for 
22
such product was deemed to be a li-
23
cense for a biological product as de-
24
scribed in clause (i).’’. 
25
Æ 
23:20 Apr 12, 2019
H2011
